An FDA panel wants the scariest warning on hormone therapy gone. The 2002 study behind it was about different women.

An expert panel convened by the FDA commissioner urged the agency today to remove the boxed warning — the agency's most severe label — from menopausal hormone therapies, beginning with low-dose vaginal estrogen. Panelists said the warnings are not supported by the data and have frightened patients and clinicians away from treatment for two decades. The warnings date to 2003, after the Women's Health Initiative trial reported higher rates of breast cancer, stroke and clots in women taking a particular hormone combination. The average participant in that trial was 63 years old, more than a decade past the typical start of menopause, and the formulation she took is no longer in common use. The label never said so.

What the evidence became. In the years since, re-analyses of the same trial and newer studies have supported a timing hypothesis: for women who start therapy under 60 or within about ten years of menopause, the balance of benefits and risks looks very different from what the 2002 headline implied, while the risks for women who start later remain. Professional societies have moved toward that view. The label did not move with them. A warning written for one population has been read by every woman in the country as if it were about her.

Loree’s take

I have spent twenty years watching women decline a treatment that might have helped them because of a box built on a trial of women a decade older than they were. That is the sex-differences problem in miniature: research done in one group, applied to everyone, for twenty years. The correction is overdue. It is also not a green light. Clots, hormone-sensitive cancers, heart disease and age at start still matter, and that is a conversation, not a label.

Ben’s take

Watch how long it takes a frightening headline to become a fact — one news cycle — and how long it takes a correction to unmake it: twenty-two years, a commissioner's panel and a public comment period. The asymmetry is not unique to hormones. It is how every scare in health works, including the ones the longevity industry runs the other way, where a hopeful mouse paper becomes a fact overnight and the null human trial never catches up.

What to watch. A panel recommendation is not a label change; the agency has to act, and it will take public comment first. The question for any reader is narrower than the policy: which population was the warning you are worried about built on, and are you in it? That question applies to every black box, and to every longevity claim, in both directions.

This post reports on evidence and expert disagreement. It is not medical advice; decisions about treatment belong with you and your clinician.